Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a strong-buy rating in a research note published on Sunday.

Other analysts have also issued reports about the stock. B. Riley assumed coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They set a “buy” rating and a $28.00 target price for the company. HC Wainwright increased their price target on shares of Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.25.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $18.94 on Friday. The stock’s 50-day simple moving average is $15.16 and its two-hundred day simple moving average is $12.78. The stock has a market capitalization of $959.69 million, a price-to-earnings ratio of 33.23 and a beta of 0.07. Theravance Biopharma has a 52-week low of $7.90 and a 52-week high of $18.97.

Institutional Trading of Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new stake in Theravance Biopharma in the 2nd quarter worth $264,000. GSA Capital Partners LLP boosted its stake in shares of Theravance Biopharma by 11.9% in the first quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company’s stock worth $1,628,000 after acquiring an additional 19,363 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Theravance Biopharma in the first quarter worth about $419,000. Acadian Asset Management LLC grew its position in shares of Theravance Biopharma by 121,993.7% during the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company’s stock worth $1,554,000 after purchasing an additional 174,451 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Theravance Biopharma by 1.5% during the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company’s stock valued at $1,049,000 after purchasing an additional 1,720 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.